Diabetes & Metabolic Syndrome-Clinical Research & Reviews最新文献_第9页

Comprehensive investigation of insulin-induced amyloidosis lesions in patients with diabetes at clinical and histological levels: A systematic review 从临床和组织学层面全面研究糖尿病患者的胰岛素诱导淀粉样变性病变：系统综述

IF 4.3 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes & Metabolic Syndrome-Clinical Research & Reviews

Pub Date : 2024-07-01 DOI: 10.1016/j.dsx.2024.103083

Leyla Karkhaneh , Shaghayegh Hosseinkhani , Hossein Azami , Yalda Karamlou , Ali Sheidaei , Ensieh Nasli-Esfahani , Farideh Razi , Azadeh Ebrahim-Habibi

Introduction

Insulin-derived amyloidosis (AIns), a skin complication in patients with diabetes, causes impaired insulin absorption. This systematic review aims to get a better understanding of this overlooked condition.

Methods

Comprehensive literature searches were performed in Scopus, PubMed, EMBASE, and Web of Science databases until June 17, 2023. From 19,343 publications, duplicate and irrelevant records were eliminated by title, and the full texts of the remaining studies were examined for validity. Clinical, pathological, and therapeutic findings were extracted from 44 papers.

Results

Forty-four articles were studied that covered 127 insulin-treated patients with diabetes. From the 62 patients with reported age and sex, males had a mean age of 58 years, and females 68.5 years. While AIns were twice as likely to develop in men (66.13 %) as in women (33.87 %), the administered insulin dose was significantly higher in males (p = 0.017). The most common insulin injection site was the abdominal wall (77.63 %). Histological findings showed the presence of amorphous material with the occasional presence of lymphocytes, plasma cells, macrophages, adipocytes, histocytes, and giant cells. The mean HbA1c level was 8.8 % and the need for receiving insulin was increased in AIns. Changing the site of insulin injections and/or surgically removing the nodules were the most common treatments to obtain better insulin uptake and controlled serum glucose levels.

Conclusion

This study highlights the importance of AIns, proper rotation of insulin injection site, and post-treatment patient follow-up to recognize and prevent the development of amyloid nodules.

导言胰岛素源性淀粉样变性（AIns）是糖尿病患者的一种皮肤并发症，会导致胰岛素吸收障碍。本系统综述旨在更好地了解这一被忽视的疾病。方法在Scopus、PubMed、EMBASE和Web of Science数据库中进行了全面的文献检索，直至2023年6月17日。从 19343 篇文献中，按标题剔除了重复和不相关的记录，并对其余研究的全文进行了有效性检查。从 44 篇论文中提取了临床、病理和治疗结果。结果研究了 44 篇文章，涉及 127 名接受过胰岛素治疗的糖尿病患者。在 62 名报告了年龄和性别的患者中，男性的平均年龄为 58 岁，女性为 68.5 岁。男性发生糖尿病的几率（66.13%）是女性（33.87%）的两倍，但男性的胰岛素注射剂量明显高于女性（p = 0.017）。最常见的胰岛素注射部位是腹壁（77.63%）。组织学检查结果显示，组织中存在无定形物质，偶见淋巴细胞、浆细胞、巨噬细胞、脂肪细胞、组织细胞和巨细胞。AIns 的平均 HbA1c 水平为 8.8%，对胰岛素的需求增加。改变胰岛素注射部位和/或手术切除结节是最常见的治疗方法，以获得更好的胰岛素吸收和控制血清葡萄糖水平。

{"title":"Comprehensive investigation of insulin-induced amyloidosis lesions in patients with diabetes at clinical and histological levels: A systematic review","authors":"Leyla Karkhaneh , Shaghayegh Hosseinkhani , Hossein Azami , Yalda Karamlou , Ali Sheidaei , Ensieh Nasli-Esfahani , Farideh Razi , Azadeh Ebrahim-Habibi","doi":"10.1016/j.dsx.2024.103083","DOIUrl":"10.1016/j.dsx.2024.103083","url":null,"abstract":"<div><h3>Introduction</h3><p>Insulin-derived amyloidosis (AIns), a skin complication in patients with diabetes, causes impaired insulin absorption. This systematic review aims to get a better understanding of this overlooked condition.</p></div><div><h3>Methods</h3><p>Comprehensive literature searches were performed in Scopus, PubMed, EMBASE, and Web of Science databases until June 17, 2023. From 19,343 publications, duplicate and irrelevant records were eliminated by title, and the full texts of the remaining studies were examined for validity. Clinical, pathological, and therapeutic findings were extracted from 44 papers.</p></div><div><h3>Results</h3><p>Forty-four articles were studied that covered 127 insulin-treated patients with diabetes. From the 62 patients with reported age and sex, males had a mean age of 58 years, and females 68.5 years. While AIns were twice as likely to develop in men (66.13 %) as in women (33.87 %), the administered insulin dose was significantly higher in males (p = 0.017). The most common insulin injection site was the abdominal wall (77.63 %). Histological findings showed the presence of amorphous material with the occasional presence of lymphocytes, plasma cells, macrophages, adipocytes, histocytes, and giant cells. The mean HbA1c level was 8.8 % and the need for receiving insulin was increased in AIns. Changing the site of insulin injections and/or surgically removing the nodules were the most common treatments to obtain better insulin uptake and controlled serum glucose levels.</p></div><div><h3>Conclusion</h3><p>This study highlights the importance of AIns, proper rotation of insulin injection site, and post-treatment patient follow-up to recognize and prevent the development of amyloid nodules.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 7","pages":"Article 103083"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141846181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Yoga and prevention of type 2 diabetes - The Indian Prevention of Diabetes Study (IPDS) 瑜伽与 2 型糖尿病的预防--印度预防糖尿病研究（IPDS）

IF 4.3 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes & Metabolic Syndrome-Clinical Research & Reviews

Pub Date : 2024-07-01 DOI: 10.1016/j.dsx.2024.103088

Sri V. Madhu , Paturi V. Rao , Hemraj B. Chandalia , Kesavadev Jothydev , Arvind Gupta , for Research Society for the Study of Diabetes in India

Background

Short term studies have reported that yoga could be beneficial in preventing diabetes. We evaluated long term effectiveness of yoga in reducing the risk of type 2 diabetes.

Methods

This open labelled randomized controlled trial was conducted across five medical centers. Adults diagnosed with prediabetes following an oral glucose tolerance test were randomly assigned to receive a structured yoga intervention consisting of 40 minutes of specific yoga asanas pranayama in addition to standard lifestyle measures or standard lifestyle measures alone. The primary outcome of incident diabetes was compared in both groups at the end of the 3-year intervention period using intention-to-treat analysis.

Results

A total of 974 individuals were randomized (488 to the yoga + lifestyle group-group1 and 486 to the Lifestyle alone group-group2). After 3 years of follow-up, there was a 39.2 % reduction of the relative risk of diabetes with yoga (11.5 % in group1 vs 18.9 % in group 2). Cox proportional hazard model analysis revealed a significantly higher odds ratio of 1.74 (95 % CI 1.25–2.43) of developing diabetes in the lifestyle alone group compared to those who also performed yoga. Adherence to yoga was good with 77 % of individuals performing yoga for more than 75 % of the time.

Conclusions

Structured yoga intervention along with standard lifestyle measures significantly reduces risk of type 2 diabetes when compared with those given lifestyle measures alone.

背景据报道，短期研究表明瑜伽有助于预防糖尿病。我们评估了瑜伽在降低 2 型糖尿病风险方面的长期有效性。方法这项开放标签随机对照试验在五个医疗中心进行。经口服葡萄糖耐量测试确诊为糖尿病前期的成人被随机分配到接受结构化瑜伽干预，其中包括在标准生活方式措施基础上进行 40 分钟的特定瑜伽体位法和呼吸法，或仅接受标准生活方式措施。结果共有 974 人被随机分配（488 人被分配到瑜伽+生活方式组1，486 人被分配到单纯生活方式组2）。经过 3 年的随访，瑜伽治疗糖尿病的相对风险降低了 39.2%（第一组为 11.5%，第二组为 18.9%）。Cox 比例危险模型分析显示，与同时进行瑜伽锻炼的人相比，单纯生活方式组患糖尿病的几率明显较高，为 1.74（95 % CI 1.25-2.43）。结论与单独采取生活方式措施的人群相比，有组织的瑜伽干预和标准生活方式措施能显著降低 2 型糖尿病的患病风险。

{"title":"Yoga and prevention of type 2 diabetes - The Indian Prevention of Diabetes Study (IPDS)","authors":"Sri V. Madhu , Paturi V. Rao , Hemraj B. Chandalia , Kesavadev Jothydev , Arvind Gupta , for Research Society for the Study of Diabetes in India","doi":"10.1016/j.dsx.2024.103088","DOIUrl":"10.1016/j.dsx.2024.103088","url":null,"abstract":"<div><h3>Background</h3><p>Short term studies have reported that yoga could be beneficial in preventing diabetes. We evaluated long term effectiveness of yoga in reducing the risk of type 2 diabetes.</p></div><div><h3>Methods</h3><p>This open labelled randomized controlled trial was conducted across five medical centers. Adults diagnosed with prediabetes following an oral glucose tolerance test were randomly assigned to receive a structured yoga intervention consisting of 40 minutes of specific yoga asanas pranayama in addition to standard lifestyle measures or standard lifestyle measures alone. The primary outcome of incident diabetes was compared in both groups at the end of the 3-year intervention period using intention-to-treat analysis.</p></div><div><h3>Results</h3><p>A total of 974 individuals were randomized (488 to the yoga + lifestyle group-group1 and 486 to the Lifestyle alone group-group2). After 3 years of follow-up, there was a 39.2 % reduction of the relative risk of diabetes with yoga (11.5 % in group1 vs 18.9 % in group 2). Cox proportional hazard model analysis revealed a significantly higher odds ratio of 1.74 (95 % CI 1.25–2.43) of developing diabetes in the lifestyle alone group compared to those who also performed yoga. Adherence to yoga was good with 77 % of individuals performing yoga for more than 75 % of the time.</p></div><div><h3>Conclusions</h3><p>Structured yoga intervention along with standard lifestyle measures significantly reduces risk of type 2 diabetes when compared with those given lifestyle measures alone.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 7","pages":"Article 103088"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141851374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between dietary protein intake and mortality among patients with diabetic kidney disease 膳食蛋白质摄入量与糖尿病肾病患者死亡率之间的关系

IF 4.3 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes & Metabolic Syndrome-Clinical Research & Reviews

Pub Date : 2024-07-01 DOI: 10.1016/j.dsx.2024.103091

Yichuan Wu , Jiaqi Chen , Yuan Tao , Manlu Xiao , Jingrong Xiong , Aomiao Chen , Xiaoqin Ma , Linna Li , Hongxia Jia , Qian Zhang , Yaoming Xue , Yijie Jia , Zongji Zheng

Aims

This study aimed to investigate the association between dietary protein intake and mortality among patients with diabetic kidney disease.

Methods

The research encompassed a total of 2901 participants diagnosed with diabetic kidney disease, drawn from the National Health and Nutrition Examination Survey (NHANES). To determine outcomes related to all-cause and cardiovascular mortality, connections were established with the National Death Index up until December 31, 2019. Estimations of hazard ratios (HRs) and their corresponding 95 % confidence intervals (CIs) were conducted using Cox proportional hazard ratio models.

Results

During the 261,239 person-years of follow-up, 1236 deaths were recorded. After multivariate adjustment, the weighted hazard ratio (HR) and 95 % CIs for participants with 1.0–1.2 g/kg of protein intake was 0.65 (0.44, 0.96) for all-cause mortality. A higher proportion of animal protein intake was found to be associated with an increased mortality risk. Stratified analyses showed that higher protein intake benefited older participants.

Conclusions

In diabetic kidney disease patients, 1.0–1.2 g/kg of protein was associated with lower mortality and 0.6–1.2 g/kg of protein especially benefitted patients ≥60 years.

目的本研究旨在调查糖尿病肾病患者膳食蛋白质摄入量与死亡率之间的关系。方法本研究从美国国家健康与营养调查（NHANES）中抽取了2901名确诊为糖尿病肾病的参与者。为了确定与全因死亡率和心血管死亡率相关的结果，研究人员与截至 2019 年 12 月 31 日的国家死亡指数建立了联系。结果在 261239 人年的随访期间，共记录了 1236 例死亡。经过多变量调整后，蛋白质摄入量为 1.0-1.2 克/千克的参与者全因死亡率的加权危险比 (HR) 和 95 % CI 为 0.65 (0.44, 0.96)。研究发现，动物蛋白摄入比例越高，死亡风险越高。结论在糖尿病肾病患者中，每公斤 1.0-1.2 克蛋白质与降低死亡率有关，每公斤 0.6-1.2 克蛋白质尤其有益于年龄≥60 岁的患者。

{"title":"Association between dietary protein intake and mortality among patients with diabetic kidney disease","authors":"Yichuan Wu , Jiaqi Chen , Yuan Tao , Manlu Xiao , Jingrong Xiong , Aomiao Chen , Xiaoqin Ma , Linna Li , Hongxia Jia , Qian Zhang , Yaoming Xue , Yijie Jia , Zongji Zheng","doi":"10.1016/j.dsx.2024.103091","DOIUrl":"10.1016/j.dsx.2024.103091","url":null,"abstract":"<div><h3>Aims</h3><p>This study aimed to investigate the association between dietary protein intake and mortality among patients with diabetic kidney disease.</p></div><div><h3>Methods</h3><p>The research encompassed a total of 2901 participants diagnosed with diabetic kidney disease, drawn from the National Health and Nutrition Examination Survey (NHANES). To determine outcomes related to all-cause and cardiovascular mortality, connections were established with the National Death Index up until December 31, 2019. Estimations of hazard ratios (HRs) and their corresponding 95 % confidence intervals (CIs) were conducted using Cox proportional hazard ratio models.</p></div><div><h3>Results</h3><p>During the 261,239 person-years of follow-up, 1236 deaths were recorded. After multivariate adjustment, the weighted hazard ratio (HR) and 95 % CIs for participants with 1.0–1.2 g/kg of protein intake was 0.65 (0.44, 0.96) for all-cause mortality. A higher proportion of animal protein intake was found to be associated with an increased mortality risk. Stratified analyses showed that higher protein intake benefited older participants.</p></div><div><h3>Conclusions</h3><p>In diabetic kidney disease patients, 1.0–1.2 g/kg of protein was associated with lower mortality and 0.6–1.2 g/kg of protein especially benefitted patients ≥60 years.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 7","pages":"Article 103091"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141843991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring effects of melatonin supplementation on insulin resistance: An updated systematic review of animal and human studies 探索补充褪黑素对胰岛素抵抗的影响：动物和人体研究的最新系统回顾

IF 4.3 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes & Metabolic Syndrome-Clinical Research & Reviews

Pub Date : 2024-07-01 DOI: 10.1016/j.dsx.2024.103073

Fakhrosadat Fayazi , Sorayya Kheirouri , Mohammad Alizadeh

Background

Insulin resistance (IR), defined as an impaired response to insulin stimulation of target tissues, is a substantial determinant of many metabolic disorders. This study aimed to update the findings of the previous systematic review evidence regarding the effect of melatonin on factors related to IR, including hyperinsulinemia, hyperglycemia, homeostasis model assessment of insulin resistance (HOMA-IR), and quantitative insulin sensitivity check index (QUICKI).

Methods

We systematically reviewed the evidence on the impact of melatonin supplementation on IR indices, fasting insulin, and fasting plasma glucose. PubMed, ScienceDirect, SCOPUS, and Google Scholar databases were searched until March 2024.

Results

We identified 6114 potentially relevant articles during the search. Eighteen animal studies and 15 randomized clinical trials met the inclusion criteria. The results indicated that melatonin supplementation reduced fasting plasma glucose (FPG, 14 out of 29 studies), fasting insulin (22 out of 28 studies), HOMA-IR (28 out of 33 studies), and increased QUICKI (7 out of 7 studies). According to RCT studies, melatonin treatment at a dosage of 10 mg reduced HOMA-IR levels in individuals with various health conditions.

Conclusion

According to most evidence, melatonin supplementation may decrease fasting insulin and HOMA-IR and increase QUICKI but may not affect FPG.

背景胰岛素抵抗（IR）是指靶组织对胰岛素刺激的反应受损，是许多代谢紊乱的重要决定因素。本研究旨在更新之前系统综述证据中有关褪黑素对 IR 相关因素（包括高胰岛素血症、高血糖、胰岛素抵抗稳态模型评估（HOMA-IR）和胰岛素敏感性定量检查指数（QUICKI））影响的研究结果。我们对 PubMed、ScienceDirect、SCOPUS 和 Google Scholar 数据库进行了检索，直至 2024 年 3 月。其中有 18 项动物研究和 15 项随机临床试验符合纳入标准。结果表明，补充褪黑素可降低空腹血浆葡萄糖（FPG，29 项研究中有 14 项）、空腹胰岛素（28 项研究中有 22 项）、HOMA-IR（33 项研究中有 28 项），并增加 QUICKI（7 项研究中有 7 项）。结论根据大多数证据，补充褪黑素可降低空腹胰岛素和 HOMA-IR 水平，增加 QUICKI，但可能不会影响 FPG。

{"title":"Exploring effects of melatonin supplementation on insulin resistance: An updated systematic review of animal and human studies","authors":"Fakhrosadat Fayazi , Sorayya Kheirouri , Mohammad Alizadeh","doi":"10.1016/j.dsx.2024.103073","DOIUrl":"10.1016/j.dsx.2024.103073","url":null,"abstract":"<div><h3>Background</h3><p>Insulin resistance (IR), defined as an impaired response to insulin stimulation of target tissues, is a substantial determinant of many metabolic disorders. This study aimed to update the findings of the previous systematic review evidence regarding the effect of melatonin on factors related to IR, including hyperinsulinemia, hyperglycemia, homeostasis model assessment of insulin resistance (HOMA-IR), and quantitative insulin sensitivity check index (QUICKI).</p></div><div><h3>Methods</h3><p>We systematically reviewed the evidence on the impact of melatonin supplementation on IR indices, fasting insulin, and fasting plasma glucose. PubMed, ScienceDirect, SCOPUS, and Google Scholar databases were searched until March 2024.</p></div><div><h3>Results</h3><p>We identified 6114 potentially relevant articles during the search. Eighteen animal studies and 15 randomized clinical trials met the inclusion criteria. The results indicated that melatonin supplementation reduced fasting plasma glucose (FPG, 14 out of 29 studies), fasting insulin (22 out of 28 studies), HOMA-IR (28 out of 33 studies), and increased QUICKI (7 out of 7 studies). According to RCT studies, melatonin treatment at a dosage of 10 mg reduced HOMA-IR levels in individuals with various health conditions.</p></div><div><h3>Conclusion</h3><p>According to most evidence, melatonin supplementation may decrease fasting insulin and HOMA-IR and increase QUICKI but may not affect FPG.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 7","pages":"Article 103073"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141852370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Practice Guidelines for the Management of Type 2 Diabetes in South Asia: A Systematic Review 南亚 2 型糖尿病管理临床实践指南：系统回顾。

IF 4.3 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes & Metabolic Syndrome-Clinical Research & Reviews

Pub Date : 2024-07-01 DOI: 10.1016/j.dsx.2024.103094

Alina Pervez , Areesha Ahmer , Omar Mahmud , Russell Seth Martins , Hawra Hussain , Sameen Nasir , Sonia Pirzada , Mohsin Ali Mustafa , Uswah Siddiqi , Maheen Zakaria , Nashia Ali Rizvi , Ainan Arshad , Adil H. Haider , Sarah Nadeem

Background

Clinical practice guidelines (CPGs) are a helpful tool for the evidence-based management of Type 2 Diabetes Mellitus (T2D). The aim of this systematic review was to synthesize and appraise the scope and quality of South Asian T2D CPGs.

Methods

This PROPSERO registered (CRD42023425150) systematic review adhered to the 2020 PRISMA guidelines. We searched the PubMed, Embase, Cochrane, and Google Scholar databases for relevant guidelines. Data synthesis was performed using a qualitative approach and methodological quality was assessed using the Appraisal of Guidelines for Research and Evaluation (AGREE) II tool.

Results

We identified eleven unique CPGs (three each from Pakistan and Sri Lanka, two from India, and one each from Bangladesh, Nepal, and Bhutan) which were published or updated between 2017 and 2023. The CPGs included recommendations regarding screening, diagnosis, prevention, and management of T2D and its acute and chronic complications, comorbidities, and fasting with T2D. The AGREE II mean domain scores ranged from 37 % to 80 %; three CPGs were ‘recommended for clinical use,’ seven were ‘recommended for use with modifications’ and one was deemed unfit for implementation.

Conclusion

The present review summarized and appraised broadly CPGs from South Asia for T2D and can help direct improvements to future iterations.

背景：临床实践指南（CPG）是对 2 型糖尿病（T2D）进行循证管理的有效工具。本系统综述旨在综合评估南亚 T2D CPGs 的范围和质量：本系统综述已在 PROPSERO 注册（CRD42023425150），符合 2020 年 PRISMA 指南。我们在 PubMed、Embase、Cochrane 和 Google Scholar 数据库中检索了相关指南。数据综合采用定性方法，方法学质量采用研究与评价指南评估（AGREE）II工具进行评估：我们确定了 11 份独特的 CPG（巴基斯坦和斯里兰卡各 3 份，印度 2 份，孟加拉国、尼泊尔和不丹各 1 份），这些 CPG 在 2017 年至 2023 年期间发布或更新。这些 CPG 包括有关 T2D 及其急性和慢性并发症、合并症以及 T2D 禁食的筛查、诊断、预防和管理的建议。AGREE II 的平均领域得分从 37% 到 80% 不等；3 份 CPGs 被 "建议用于临床"，7 份被 "建议在修改后使用"，1 份被认为不适合实施：本综述对南亚地区针对 T2D 的 CPG 进行了广泛的总结和评估，有助于指导今后的迭代改进。

{"title":"Clinical Practice Guidelines for the Management of Type 2 Diabetes in South Asia: A Systematic Review","authors":"Alina Pervez , Areesha Ahmer , Omar Mahmud , Russell Seth Martins , Hawra Hussain , Sameen Nasir , Sonia Pirzada , Mohsin Ali Mustafa , Uswah Siddiqi , Maheen Zakaria , Nashia Ali Rizvi , Ainan Arshad , Adil H. Haider , Sarah Nadeem","doi":"10.1016/j.dsx.2024.103094","DOIUrl":"10.1016/j.dsx.2024.103094","url":null,"abstract":"<div><h3>Background</h3><p>Clinical practice guidelines (CPGs) are a helpful tool for the evidence-based management of Type 2 Diabetes Mellitus (T2D). The aim of this systematic review was to synthesize and appraise the scope and quality of South Asian T2D CPGs.</p></div><div><h3>Methods</h3><p>This PROPSERO registered (CRD42023425150) systematic review adhered to the 2020 PRISMA guidelines. We searched the PubMed, Embase, Cochrane, and Google Scholar databases for relevant guidelines. Data synthesis was performed using a qualitative approach and methodological quality was assessed using the Appraisal of Guidelines for Research and Evaluation (AGREE) II tool.</p></div><div><h3>Results</h3><p>We identified eleven unique CPGs (three each from Pakistan and Sri Lanka, two from India, and one each from Bangladesh, Nepal, and Bhutan) which were published or updated between 2017 and 2023. The CPGs included recommendations regarding screening, diagnosis, prevention, and management of T2D and its acute and chronic complications, comorbidities, and fasting with T2D. The AGREE II mean domain scores ranged from 37 % to 80 %; three CPGs were ‘recommended for clinical use,’ seven were ‘recommended for use with modifications’ and one was deemed unfit for implementation.</p></div><div><h3>Conclusion</h3><p>The present review summarized and appraised broadly CPGs from South Asia for T2D and can help direct improvements to future iterations.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 7","pages":"Article 103094"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Asprosin levels in patients with type 2 diabetes mellitus, metabolic syndrome and obesity: A systematic review and meta-analysis 2 型糖尿病、代谢综合征和肥胖症患者体内的阿司匹林水平：系统回顾与荟萃分析。

IF 4.3 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes & Metabolic Syndrome-Clinical Research & Reviews

Pub Date : 2024-07-01 DOI: 10.1016/j.dsx.2024.103095

Juan R. Ulloque-Badaracco , Ali Al-kassab-Córdova , Enrique A. Hernandez-Bustamante , Esteban A. Alarcon-Braga , Pamela Robles-Valcarcel , Miguel A. Huayta-Cortez , Juan C. Cabrera Guzmán , Rosa A. Seminario-Amez , Vicente A. Benites-Zapata

Background & aims

Asprosin is a promising candidate for novel treatments for metabolic–endocrine disorders. The objective of this systematic review and meta-analysis was to consolidate the existing evidence regarding asprosin levels in patients diagnosed with type 2 diabetes (T2D), metabolic syndrome (MetS), and obesity.

Methods

Scopus, Embase, PubMed, Ovid/Medline, and Web of Science were systematically searched without restrictions. We only used the standardized mean differences (SMD) with their 95 % confidence intervals (95 % CI) as the effect measure. A random-effects model (DerSimonian and Laird method) was used for the meta-analysis. Risk of bias was assessed with the Newcastle–Ottawa Scale and Newcastle–Ottawa Scale for Cross-Sectional Studies.

Results

Twenty-six studies (n = 3,787) were included in the meta-analysis. Participants with T2D had higher asprosin values than those without T2D (SMD: 1.64; 95 % CI: 1.08–2.21; I² = 97 %). Patients with MetS had higher asprosin levels compared to those without MetS (SMD: 0.99; 95 % CI: 0.34–1.64; I² = 96 %). Patients with obesity had higher asprosin levels than participants without obesity (SMD: 1.49; 95 % CI: 0.23–2.76; I² = 98 %).

Conclusions

Asprosin is significantly higher in patients with either T2D, MetS, or obesity, compared with controls.

背景和目的：阿司匹林是一种治疗代谢内分泌紊乱的新型候选药物。本系统综述和荟萃分析的目的是整合有关确诊为 2 型糖尿病（T2D）、代谢综合征（MetS）和肥胖症患者体内阿司匹林水平的现有证据：对 Scopus、Embase、PubMed、Ovid/Medline 和 Web of Science 进行了无限制的系统检索。我们仅使用标准化均值差异（SMD）及其 95 % 置信区间（95 % CI）作为效应测量指标。荟萃分析采用随机效应模型（DerSimonian 和 Laird 方法）。采用纽卡斯尔-渥太华量表（Newcastle-Ottawa Scale）和纽卡斯尔-渥太华横断面研究量表（Newcastle-Ottawa Scale for Cross-Sectional Studies）评估偏倚风险：荟萃分析纳入了 26 项研究（n = 3787）。患有 T2D 的参与者的asprosin值高于未患 T2D 的参与者（SMD：1.64；95 % CI：1.08-2.21；I2 = 97 %）。与非 MetS 患者相比，MetS 患者的asprosin 水平更高（SMD：0.99；95 % CI：0.34-1.64；I2 = 96 %）。肥胖症患者的asprosin水平高于非肥胖症患者（SMD：1.49；95 % CI：0.23-2.76；I2 = 98 %）：与对照组相比，患有 T2D、MetS 或肥胖症的患者体内的阿司匹林含量明显更高。

{"title":"Asprosin levels in patients with type 2 diabetes mellitus, metabolic syndrome and obesity: A systematic review and meta-analysis","authors":"Juan R. Ulloque-Badaracco , Ali Al-kassab-Córdova , Enrique A. Hernandez-Bustamante , Esteban A. Alarcon-Braga , Pamela Robles-Valcarcel , Miguel A. Huayta-Cortez , Juan C. Cabrera Guzmán , Rosa A. Seminario-Amez , Vicente A. Benites-Zapata","doi":"10.1016/j.dsx.2024.103095","DOIUrl":"10.1016/j.dsx.2024.103095","url":null,"abstract":"<div><h3>Background & aims</h3><p>Asprosin is a promising candidate for novel treatments for metabolic–endocrine disorders. The objective of this systematic review and meta-analysis was to consolidate the existing evidence regarding asprosin levels in patients diagnosed with type 2 diabetes (T2D), metabolic syndrome (MetS), and obesity.</p></div><div><h3>Methods</h3><p>Scopus, Embase, PubMed, Ovid/Medline, and Web of Science were systematically searched without restrictions. We only used the standardized mean differences (SMD) with their 95 % confidence intervals (95 % CI) as the effect measure. A random-effects model (DerSimonian and Laird method) was used for the meta-analysis. Risk of bias was assessed with the Newcastle–Ottawa Scale and Newcastle–Ottawa Scale for Cross-Sectional Studies.</p></div><div><h3>Results</h3><p>Twenty-six studies (n = 3,787) were included in the meta-analysis. Participants with T2D had higher asprosin values than those without T2D (SMD: 1.64; 95 % CI: 1.08–2.21; I<sup>2</sup> = 97 %). Patients with MetS had higher asprosin levels compared to those without MetS (SMD: 0.99; 95 % CI: 0.34–1.64; I<sup>2</sup> = 96 %). Patients with obesity had higher asprosin levels than participants without obesity (SMD: 1.49; 95 % CI: 0.23–2.76; I<sup>2</sup> = 98 %).</p></div><div><h3>Conclusions</h3><p>Asprosin is significantly higher in patients with either T2D, MetS, or obesity, compared with controls.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 7","pages":"Article 103095"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141890499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genetic association of glycemic traits and antihyperglycemic agent target genes with the risk of lung cancer: A Mendelian randomization study 血糖特征和降糖药靶基因与肺癌风险的遗传关联：孟德尔随机研究

IF 1 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes & Metabolic Syndrome-Clinical Research & Reviews

Pub Date : 2024-06-01 DOI: 10.1016/j.dsx.2024.103048

Wen Sun , Xiaoyu Zhang , Ning Li , Yan He , Jianguang Ji , Deqiang Zheng

Aims

To evaluate the potential causal effect of glycemic traits on lung cancer and investigate the impact of antihyperglycemic agent-target genes on lung cancer risk.

Methods

Genetic variants associated with glycemic traits, antihyperglycemic agent-target genes, and lung cancer were extracted from the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC), expression quantitative trait loci (eQTLs), protein quantitative trait loci (pQTLs), and the International Lung Cancer Consortium (ILCCO), respectively. Mendelian randomization (MR) analyses were performed to examine the associations of glycemic traits and antihyperglycemic agent-target genes with lung cancer. Mediation analysis was conducted to explore whether overweight operated as a mediator between antihyperglycemic agents and lung cancer outcomes.

Results

Genetically determined glycated hemoglobin A1c levels were associated with squamous cell lung cancer (OR = 1.78; 95 % CI, 1.08–2.92; p = 0.023). The PRKAB1 gene (the target of metformin) was associated with a lower risk of developing lung adenocarcinoma (OR = 0.85; 95 % CI, 0.76–0.96; p = 0.006). Further mediation analyses did not support overweight as a mediator between PRKAB1 activation and lung adenocarcinoma.

Conclusion

Our analyses suggest an association of genetically determined abnormal glycemic traits with squamous cell lung cancer. The potential association between PRKAB1 activation and a reduced risk of developing lung adenocarcinoma appears to be independent of the anti-obesity effects of metformin, suggesting that PRKAB1 activation may have a direct protective effect on lung adenocarcinoma development.

目的评估血糖特征对肺癌的潜在因果效应，并研究抗高血糖药靶基因对肺癌风险的影响。方法分别从葡萄糖和胰岛素相关性状联合会（MAGIC）、表达定量性状位点（eQTLs）、蛋白质定量性状位点（pQTLs）和国际肺癌联合会（ILCCO）中提取与血糖性状、降糖药靶基因和肺癌相关的遗传变异。通过孟德尔随机化（MR）分析，研究了血糖性状和降糖药靶基因与肺癌的关系。结果基因测定的糖化血红蛋白 A1c 水平与鳞状细胞肺癌相关（OR = 1.78；95 % CI，1.08-2.92；p = 0.023）。PRKAB1基因（二甲双胍的靶基因）与较低的肺腺癌发病风险相关（OR = 0.85；95 % CI，0.76-0.96；p = 0.006）。进一步的中介分析不支持超重作为 PRKAB1 激活与肺腺癌之间的中介。PRKAB1激活与肺腺癌发病风险降低之间的潜在关联似乎与二甲双胍的抗肥胖作用无关，这表明PRKAB1激活可能对肺腺癌的发病有直接的保护作用。

{"title":"Genetic association of glycemic traits and antihyperglycemic agent target genes with the risk of lung cancer: A Mendelian randomization study","authors":"Wen Sun , Xiaoyu Zhang , Ning Li , Yan He , Jianguang Ji , Deqiang Zheng","doi":"10.1016/j.dsx.2024.103048","DOIUrl":"10.1016/j.dsx.2024.103048","url":null,"abstract":"<div><h3>Aims</h3><p>To evaluate the potential causal effect of glycemic traits on lung cancer and investigate the impact of antihyperglycemic agent-target genes on lung cancer risk.</p></div><div><h3>Methods</h3><p>Genetic variants associated with glycemic traits, antihyperglycemic agent-target genes, and lung cancer were extracted from the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC), expression quantitative trait loci (eQTLs), protein quantitative trait loci (pQTLs), and the International Lung Cancer Consortium (ILCCO), respectively. Mendelian randomization (MR) analyses were performed to examine the associations of glycemic traits and antihyperglycemic agent-target genes with lung cancer. Mediation analysis was conducted to explore whether overweight operated as a mediator between antihyperglycemic agents and lung cancer outcomes.</p></div><div><h3>Results</h3><p>Genetically determined glycated hemoglobin A1c levels were associated with squamous cell lung cancer (OR = 1.78; 95 % CI, 1.08–2.92; <em>p</em> = 0.023). The <em>PRKAB1</em> gene (the target of metformin) was associated with a lower risk of developing lung adenocarcinoma (OR = 0.85; 95 % CI, 0.76–0.96; <em>p</em> = 0.006). Further mediation analyses did not support overweight as a mediator between <em>PRKAB1</em> activation and lung adenocarcinoma.</p></div><div><h3>Conclusion</h3><p>Our analyses suggest an association of genetically determined abnormal glycemic traits with squamous cell lung cancer. The potential association between <em>PRKAB1</em> activation and a reduced risk of developing lung adenocarcinoma appears to be independent of the anti-obesity effects of metformin, suggesting that <em>PRKAB1</em> activation may have a direct protective effect on lung adenocarcinoma development.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 6","pages":"Article 103048"},"PeriodicalIF":10.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141281776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effectiveness of chia seed in improving glycemic status: A systematic review and meta-analysis 奇异籽在改善血糖状况方面的功效：系统回顾和荟萃分析。

IF 4.3 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes & Metabolic Syndrome-Clinical Research & Reviews

Pub Date : 2024-06-01 DOI: 10.1016/j.dsx.2024.103065

Pedram Pam , Iman El Sayed , Sanaz Asemani , Parsa Jamilian , Meysam Zarezadeh , Zohreh Ghoreishy

Aims

This systematic review and meta-analysis aims to evaluate the effectiveness of chia seeds in improving glycemic status, including fasting blood glucose (FBG), glycated hemoglobin (HbA1c), and insulin.

Methods

A comprehensive literature search was conducted on PubMed, Scopus, Web of Science, Cochrane, and Google Scholar up to January 2024. Randomized controlled trials (RCTs) assessing the effect of chia seeds on FBG, HbA1c, and/or insulin that meet our eligibility criteria were included. Version 2 of the Cochrane risk-of-bias tool (RoB2) was used to assess the quality of the included studies. Data were extracted and analyzed using a random-effects model and reported as weighted mean differences (WMD) with 95 % confidence intervals (CI). Subgroup and sensitivity analyses were also performed. The registration number was CRD42023441766.

Results

Out of 341 articles retrieved from the initial search, 8 RCTs (with 10 arms) involving 362 participants were included in the meta-analysis. The results showed that chia consumption had no significant effect on FBG (WMD: 0.79 %; 95 % CI: −0.97 to 2.55; p = 0.38), HbA1c (WMD: −0.12 %; 95 % CI: −0.27 to 0.02; p = 0.09), and insulin (WMD:1.23 %; 95 % CI: −1.77 to 4.22; p = 0.42).

Conclusions

Chia seed consumption shows no significant impact on FBG, HbA1c, and insulin levels. This study is limited by the small number of studies in the meta-analysis and the significant heterogeneity among them, necessitating further research with larger sample sizes.

目的：本系统综述和荟萃分析旨在评估奇异籽在改善血糖状况（包括空腹血糖（FBG）、糖化血红蛋白（HbA1c）和胰岛素）方面的有效性：方法：在 PubMed、Scopus、Web of Science、Cochrane 和 Google Scholar 上对截至 2024 年 1 月的文献进行了全面检索。纳入符合资格标准的评估奇异籽对 FBG、HbA1c 和/或胰岛素影响的随机对照试验（RCT）。科克伦偏倚风险工具（RoB2）第 2 版用于评估纳入研究的质量。采用随机效应模型提取和分析数据，并以加权平均差 (WMD) 和 95% 置信区间 (CI) 的形式进行报告。此外，还进行了分组分析和敏感性分析。注册编号为 CRD42023441766：在最初检索到的 341 篇文章中，有 8 项 RCT（共 10 个研究组）被纳入荟萃分析，涉及 362 名参与者。结果显示，食用奇异籽对 FBG（WMD：0.79 %；95 % CI：-0.97 至 2.55；p = 0.38）、HbA1c（WMD：-0.12 %；95 % CI：-0.27 至 0.02；p = 0.09）和胰岛素（WMD：1.23 %；95 % CI：-1.77 至 4.22；p = 0.42）没有显著影响：结论：食用奇异籽对 FBG、HbA1c 和胰岛素水平没有明显影响。由于荟萃分析中的研究数量较少，且这些研究之间存在明显的异质性，因此本研究受到了一定的限制，有必要进行样本量更大的进一步研究。

{"title":"The effectiveness of chia seed in improving glycemic status: A systematic review and meta-analysis","authors":"Pedram Pam , Iman El Sayed , Sanaz Asemani , Parsa Jamilian , Meysam Zarezadeh , Zohreh Ghoreishy","doi":"10.1016/j.dsx.2024.103065","DOIUrl":"10.1016/j.dsx.2024.103065","url":null,"abstract":"<div><h3>Aims</h3><p>This systematic review and meta-analysis aims to evaluate the effectiveness of chia seeds in improving glycemic status, including fasting blood glucose (FBG), glycated hemoglobin (HbA1c), and insulin.</p></div><div><h3>Methods</h3><p>A comprehensive literature search was conducted on PubMed, Scopus, Web of Science, Cochrane, and Google Scholar up to January 2024. Randomized controlled trials (RCTs) assessing the effect of chia seeds on FBG, HbA1c, and/or insulin that meet our eligibility criteria were included. Version 2 of the Cochrane risk-of-bias tool (RoB2) was used to assess the quality of the included studies. Data were extracted and analyzed using a random-effects model and reported as weighted mean differences (WMD) with 95 % confidence intervals (CI). Subgroup and sensitivity analyses were also performed. The registration number was <strong>CRD42023441766</strong>.</p></div><div><h3>Results</h3><p>Out of 341 articles retrieved from the initial search, 8 RCTs (with 10 arms) involving 362 participants were included in the meta-analysis. The results showed that chia consumption had no significant effect on FBG (WMD: 0.79 %; 95 % CI: −0.97 to 2.55; <em>p</em> = 0.38), HbA1c (WMD: −0.12 %; 95 % CI: −0.27 to 0.02; <em>p</em> = 0.09), and insulin (WMD:1.23 %; 95 % CI: −1.77 to 4.22; <em>p</em> = 0.42).</p></div><div><h3>Conclusions</h3><p>Chia seed consumption shows no significant impact on FBG, HbA1c, and insulin levels. This study is limited by the small number of studies in the meta-analysis and the significant heterogeneity among them, necessitating further research with larger sample sizes.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 6","pages":"Article 103065"},"PeriodicalIF":4.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141451908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Life's Essential 8 and risks of cardiovascular morbidity and mortality among individuals with type 2 diabetes: A cohort study 生活必备 8》与 2 型糖尿病患者的心血管发病率和死亡率风险：一项队列研究。

IF 4.3 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes & Metabolic Syndrome-Clinical Research & Reviews

Pub Date : 2024-06-01 DOI: 10.1016/j.dsx.2024.103066

Hanzhang Wu , Jiahe Wei , Shuai Wang , Wenjuan Chen , Liangkai Chen , Jihui Zhang , Ningjian Wang , Xiao Tan

Background

The association of cardiovascular health levels, as measured by the Life's Essential 8 score, with cardiovascular disease (CVD) incidence and mortality among individuals with type 2 diabetes (T2D) has not been fully elucidated.

Methods

This cohort study included 15,118 participants with T2D from the UK Biobank who were free of CVD and cancer at baseline. The cardiovascular health of participants was evaluated using the Life's Essential 8 score, categorizing their health levels into low, moderate, and high based on this assessment.

Results

During a median follow-up period of 13.0 years, we observed a total of 4421 cases of CVD, comprising 3467 cases of coronary heart disease (CHD), 811 cases of stroke, 1465 cases of heart failure (HF), and 523 cases of CVD mortality. Compared to participants with low cardiovascular health, those with high cardiovascular health had a 52 %, 50 %, 47 %, 67 %, and 51 % lower risk of CVD, CHD, stroke, HF, and CVD mortality, respectively. Among the components of the Life's Essential 8 score, body mass index showed the highest population attributable risk of 12.1 %. Similar findings were observed in joint analyses of cardiovascular health and diabetes severity status.

Conclusions

This study emphasizes the importance of maintaining good cardiovascular health among individuals with T2D to reduce their risk of CVD incidence and mortality.

背景：在 2 型糖尿病（T2D）患者中，心血管健康水平（以生命必备 8 项评分衡量）与心血管疾病（CVD）发病率和死亡率之间的关系尚未完全阐明：这项队列研究包括英国生物库中的 15118 名 2 型糖尿病患者，他们在基线时没有心血管疾病和癌症。研究人员使用 "生命必备 8 "评分标准对参与者的心血管健康状况进行了评估，并根据评估结果将他们的健康水平分为低、中、高三个等级：在中位 13.0 年的随访期间，我们共观察到 4421 例心血管疾病，其中包括 3467 例冠心病（CHD）、811 例中风、1465 例心力衰竭（HF）和 523 例心血管疾病死亡。与心血管健康水平低的参与者相比，心血管健康水平高的参与者患心血管疾病、冠心病、中风、心力衰竭和心血管疾病死亡的风险分别低 52%、50%、47%、67% 和 51%。在 "生命必备 8 要素 "的各组成部分中，体重指数显示的人群归因风险最高，为 12.1%。在对心血管健康和糖尿病严重程度进行联合分析时也观察到了类似的结果：这项研究强调了保持 T2D 患者良好的心血管健康对降低其心血管疾病发病率和死亡率风险的重要性。

{"title":"Life's Essential 8 and risks of cardiovascular morbidity and mortality among individuals with type 2 diabetes: A cohort study","authors":"Hanzhang Wu , Jiahe Wei , Shuai Wang , Wenjuan Chen , Liangkai Chen , Jihui Zhang , Ningjian Wang , Xiao Tan","doi":"10.1016/j.dsx.2024.103066","DOIUrl":"10.1016/j.dsx.2024.103066","url":null,"abstract":"<div><h3>Background</h3><p>The association of cardiovascular health levels, as measured by the Life's Essential 8 score, with cardiovascular disease (CVD) incidence and mortality among individuals with type 2 diabetes (T2D) has not been fully elucidated.</p></div><div><h3>Methods</h3><p>This cohort study included 15,118 participants with T2D from the UK Biobank who were free of CVD and cancer at baseline. The cardiovascular health of participants was evaluated using the Life's Essential 8 score, categorizing their health levels into low, moderate, and high based on this assessment.</p></div><div><h3>Results</h3><p>During a median follow-up period of 13.0 years, we observed a total of 4421 cases of CVD, comprising 3467 cases of coronary heart disease (CHD), 811 cases of stroke, 1465 cases of heart failure (HF), and 523 cases of CVD mortality. Compared to participants with low cardiovascular health, those with high cardiovascular health had a 52 %, 50 %, 47 %, 67 %, and 51 % lower risk of CVD, CHD, stroke, HF, and CVD mortality, respectively. Among the components of the Life's Essential 8 score, body mass index showed the highest population attributable risk of 12.1 %. Similar findings were observed in joint analyses of cardiovascular health and diabetes severity status.</p></div><div><h3>Conclusions</h3><p>This study emphasizes the importance of maintaining good cardiovascular health among individuals with T2D to reduce their risk of CVD incidence and mortality.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 6","pages":"Article 103066"},"PeriodicalIF":4.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141471676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between urate-lowering therapy initiation and all-cause mortality in patients with type 2 diabetes and asymptomatic hyperuricemia 2 型糖尿病和无症状高尿酸血症患者开始接受降尿酸治疗与全因死亡率之间的关系

IF 4.3 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes & Metabolic Syndrome-Clinical Research & Reviews

Pub Date : 2024-06-01 DOI: 10.1016/j.dsx.2024.103043

Ruixuan Chen , Sheng Nie , Shiyu Zhou , Licong Su , Yanqin Li , Xiaodong Zhang , Fan Luo , Ruqi Xu , Qi Gao , Yuxin Lin , Zhixin Guo , Lisha Cao , Xin Xu

Aims

To assess the relationships between urate-lowering therapy (ULT) initiation with all-cause mortality in patients with asymptomatic hyperuricemia and Type 2 Diabetes (T2D).

Methods

This nationwide retrospective cohort study involved patients with T2D and asymptomatic hyperuricemia from 19 academic hospitals across China between 2000 and 2021. The primary exposure was ULT initiation, including allopurinol, febuxostat, or benzbromarone. The primary outcome was all-cause mortality. The secondary outcomes were cardiovascular (CV) and non-CV mortality. Propensity score matching was employed to create a 1:2 matched cohort with balanced likelihood of ULT initiation. Associations between ULT initiation with all-cause and CV mortality were assessed in the matched cohort.

Results

Among 42 507 patients, 5028 initiated ULT and 37 479 did not. In the matched cohort, comprising 4871 ULT initiators and 9047 noninitiators, ULT initiation was significantly associated with reduced risk of all-cause mortality (hazard ratio [HR] 0.77; 95% confidence interval [CI], 0.71–0.84), CV mortality (HR 0.86; 95% CI, 0.76–0.97), and non-CV mortality (HR 0.72; 95% CI, 0.64–0.80) over an average 3.0 years of follow-up. Among the ULT initiators, post-treatment SUA levels of 360–420 μmol/L was related to a significantly lower risk for all-cause mortality compared to levels >420 μmol/L (HR 0.74; 95% CI, 0.59–0.94) while levels ≤360 μmol/L did not (HR, 0.96; 95% CI, 0.81–1.14), suggesting a U-shaped relationship.

Conclusions

Initiating ULT was associated with a significant reduction in all-cause mortality in patients with T2D and asymptomatic hyperuricemia. Notably, maintaining post-treatment SUA concentrations within 360–420 μmol/L could potentially enhance this reduced mortality.

目的评估无症状高尿酸血症和 2 型糖尿病（T2D）患者开始接受降尿酸治疗（ULT）与全因死亡率之间的关系。方法这项全国性回顾性队列研究涉及 2000 年至 2021 年期间中国 19 家学术医院的 T2D 和无症状高尿酸血症患者。主要暴露是开始使用超低浓度治疗，包括别嘌醇、非布司他或苯溴马隆。主要结果为全因死亡率。次要结果为心血管 (CV) 和非 CV 死亡率。该研究采用倾向评分匹配法建立了1:2的匹配队列，且开始使用超短波治疗的可能性均衡。结果在 42 507 名患者中，5028 人开始使用 ULT，37 479 人未使用。在由 4871 名 ULT 启动者和 9047 名非启动者组成的匹配队列中，在平均 3.0 年的随访期间，ULT 启动与全因死亡风险降低（危险比 [HR] 0.77；95% 置信区间 [CI]，0.71-0.84）、CV 死亡率（HR 0.86；95% CI，0.76-0.97）和非 CV 死亡率（HR 0.72；95% CI，0.64-0.80）显著相关。在ULT启动者中，与>420 μmol/L水平相比，治疗后SUA水平为360-420 μmol/L与全因死亡风险显著降低有关（HR为0.74；95% CI为0.59-0.94），而≤360 μmol/L水平与全因死亡风险无关（HR为0.结论在患有 T2D 和无症状高尿酸血症的患者中，启动 ULT 可显著降低全因死亡率。值得注意的是，将治疗后的 SUA 浓度维持在 360-420 μmol/L 的范围内可能会提高死亡率的降低幅度。

{"title":"Association between urate-lowering therapy initiation and all-cause mortality in patients with type 2 diabetes and asymptomatic hyperuricemia","authors":"Ruixuan Chen , Sheng Nie , Shiyu Zhou , Licong Su , Yanqin Li , Xiaodong Zhang , Fan Luo , Ruqi Xu , Qi Gao , Yuxin Lin , Zhixin Guo , Lisha Cao , Xin Xu","doi":"10.1016/j.dsx.2024.103043","DOIUrl":"10.1016/j.dsx.2024.103043","url":null,"abstract":"<div><h3>Aims</h3><p>To assess the relationships between urate-lowering therapy (ULT) initiation with all-cause mortality in patients with asymptomatic hyperuricemia and Type 2 Diabetes (T2D).</p></div><div><h3>Methods</h3><p>This nationwide retrospective cohort study involved patients with T2D and asymptomatic hyperuricemia from 19 academic hospitals across China between 2000 and 2021. The primary exposure was ULT initiation, including allopurinol, febuxostat, or benzbromarone. The primary outcome was all-cause mortality. The secondary outcomes were cardiovascular (CV) and non-CV mortality. Propensity score matching was employed to create a 1:2 matched cohort with balanced likelihood of ULT initiation. Associations between ULT initiation with all-cause and CV mortality were assessed in the matched cohort.</p></div><div><h3>Results</h3><p>Among 42 507 patients, 5028 initiated ULT and 37 479 did not. In the matched cohort, comprising 4871 ULT initiators and 9047 noninitiators, ULT initiation was significantly associated with reduced risk of all-cause mortality (hazard ratio [HR] 0.77; 95% confidence interval [CI], 0.71–0.84), CV mortality (HR 0.86; 95% CI, 0.76–0.97), and non-CV mortality (HR 0.72; 95% CI, 0.64–0.80) over an average 3.0 years of follow-up. Among the ULT initiators, post-treatment SUA levels of 360–420 μmol/L was related to a significantly lower risk for all-cause mortality compared to levels >420 μmol/L (HR 0.74; 95% CI, 0.59–0.94) while levels ≤360 μmol/L did not (HR, 0.96; 95% CI, 0.81–1.14), suggesting a U-shaped relationship.</p></div><div><h3>Conclusions</h3><p>Initiating ULT was associated with a significant reduction in all-cause mortality in patients with T2D and asymptomatic hyperuricemia. Notably, maintaining post-treatment SUA concentrations within 360–420 μmol/L could potentially enhance this reduced mortality.</p></div>","PeriodicalId":48252,"journal":{"name":"Diabetes & Metabolic Syndrome-Clinical Research & Reviews","volume":"18 6","pages":"Article 103043"},"PeriodicalIF":4.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141131877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0